Evaluate the efficacy and safety of orelabrutinib, tafasitamab, and lenalidomide in the first-line treatment of patients with follicular lymphoma.
Age > 18 years, regardless of gender;
Newly diagnosed patients with follicular lymphoma (Grade 1, 2, or 3a) confirmed histologicallyaccording to the World Health Organization (WHO) classification of diseases;
Deemed by the investigator to have an indication for treatment and require therapy;
ECOG performance status score of 0-2;
Women with a positive serum pregnancy test or who are breastfeeding;
Patients with lymphoma involving the central nervous system (CNS);
Clinically significant heart disease, including unstable angina, acute myocardial infarction within6 months prior to randomization, congestive heart failure with New York Heart Association(NYHA) functional class IIl or IV, or left ventricular ejection fraction <50%;
Patients with grade >2 neuropathy;